Open AccessExploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
Author(s) -
Amy Cutrell,
Jonathan Schapiro,
Carlo Federico Perno,
Daniel R. Kuritzkes,
Romina Quercia,
Parul Patel,
Joseph W. Polli,
David Dorey,
Yongwei Wang,
Sterling Wu,
Veerle Van Eygen,
Herta Crauwels,
Susan L. Ford,
Mark Baker,
Christine L. Talarico,
Marty St. Clair,
Jerry Jeffrey,
Carl White,
Simon Vanveggel,
Kati Vandermeulen,
David Margolis,
Michael Aboud,
William Spreen,
Jan van Lunzen
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002883
Subject(s) - rilpivirine , medicine , logistic regression , odds ratio , dosing , regimen , viral load , post hoc analysis , human immunodeficiency virus (hiv) , virology , antiretroviral therapy
Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here, factors associated with virologic failure at Week 48 were evaluated post hoc.